Sleep_disorders - Articles - Page 2

Insomnia and Substance Use Disorders

April 10, 2019

Nicholas Rosenlicht, MD

Clinical Professor of Psychiatry, University of California, San Francisco, School of Medicine. Founder and served for 15 years as the director of the UCSF-VAMC Mood Disorders Clinic. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Sleep problems are common in recovery, and they have many causes such as withdrawal states, circadian rhythm disruptions, and a host of psychiatric and medical comorbidities. It’s a two-way street: Insomnia raises the risk of substance misuse, and addiction can cause or worsen sleep problems.

Jornay PM Nighttime Stimulant for Next-Morning Effect

November 1, 2018

Talia Puzantian, PharmD, BCPP

Talia Puzantian, PharmD, BCPP Dr. Puzantian has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Prescribing bedtime stimulants sounds like a recipe for a bad night’s sleep. But the FDA recently approved Jornay PM, which is an extended release (ER) formulation of methylphenidate that is, in fact, dosed at night.

Sleep Apnea in Patients With Substance Use Disorders: A Primer

August 23, 2018

Rehan Aziz, MD

Rehan Aziz, MD Associate Professor of Psychiatry and Neurology, Rutgers University—Robert Wood Johnson Medical School Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are three types of sleep apnea: obstructive sleep apnea (OSA), central sleep apnea, and mixed. Of these, OSA is by far the most common, and that’s what we’ll focus on in this article. OSA is caused by excessive relaxation of the throat during sleep, which in some people causes enough obstruction to impede the flow of air.

Treating Insomnia With Addiction

August 23, 2018

Eric Hermes, MD

Eric Hermes, MD Assistant Professor, Department of Psychiatry, Yale School of Medicine, New Haven, CT Dr. Hermes has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With substance use disorders (SUDs) that are comorbid with chronic insomnia, what would you say are some of the main treatment challenges?

Non-Addictive, Pharmacological Options for Sleep

August 23, 2018

Daniel Carlat, MD

Daniel Carlat, MD Publisher, The Carlat Addiction Treatment Report Dr. Carlat has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this month’s interview with Dr. Eric Hermes, we learned about his approach to treating insomnia in patients with substance use disorders, with a focus on cognitive behavioral therapy. In this article, we’ll look at some non-addictive pharmacological options.

Cognitive Behavior Therapy for Insomnia

April 1, 2017

Michael Perlis, PhD

Michael Perlis, PhD Associate professor of psychiatry & nursing, University of Pennsylvania. Director, UPenn Behavioral Sleep Medicine Program Dr. Perlis has disclosed that he has received funding for research on CBT-I and has received funds from the sales of materials related to the teaching of CBT-I techniques. Dr. Carlat has reviewed this interview and has found no evidence of bias in this educational activity.

Insomnia is so ubiquitous and misunderstood with respect to its health consequences and “treatability.” At the core of this is the widespread misconception that insomnia is primarily a symptom of other things. Insomnia is also identified in DSM-5 as an independent disorder (780.52) which, when occurring with other DSM-5 disorders, is considered a comorbid disorder rather than a symptom.

Disrupted Sleep: Approaches to Assessment and Treatment in Children and Adolescents

March 1, 2016

Ian Lee, DO

This article describes some of the more common sleep disorders of childhood and presents the cornerstone for diagnosing pediatric sleep disorders as obtaining a detailed and accurate history followed by a comprehensive physical exam that includes screening for developmental delays and cognitive dysfunction.

Got Zeitgebers? You Should

March 1, 2016

Rafael Pelayo, MD

This article describes some of the more common sleep disorders of childhood and presents the cornerstone for diagnosing pediatric sleep disorders as obtaining a detailed and accurate history followed by a comprehensive physical exam that includes screening for developmental delays and cognitive dysfunction.

EXPERT Q&A

Poor Sleep in Children and Adolescents: A Primer

March 1, 2016

Rafael Pelayo, MD, FAASM

CCPR_DrPelayo_photo_Q&A.jpg Rafael Pelayo, MD.

Clinical Professor in the Department of Psychiatry and Behavioral Sciences, Stanford Center for Sleep Sciences and Medicine at the Stanford University School of Medicine, Stanford, CA.

Dr. Pelayo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The more important issue with sleep disorders is not so much the number of hours of sleep; it’s whether the child wakes up refreshed or not. Sleeping is about restoring the brain.Dr. Pelayo discusses his approach to treating sleep disorders, focusing on the key areas clinicians need to cover when getting a patient’s history.

A Narcolepsy Primer, With a Focus on Xyrem

September 1, 2015

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Talia Puzantian, PharmD, BCPP Clinical psychopharmacology consultant in private practice, Los Angeles, CA. www.taliapuzantian.com Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Narcolepsy affects about 1 out of 2000 people, for a prevalence rate of 0.05%. This puts it officially in the category of rare diseases. So why are we asking you to read about such a rare disorder? Partly because there’s a lot of comorbidity between narcolepsy and most psychiatric disorders. And partly because Jazz Pharmaceuticals is placing lots of ads in psychiatric journals urging us to diagnose more narcolepsy so that we’ll use their new drug Xyrem.